Gγ-Xmn I polymorphism: A significant determinant of β-thalassemia treatment without blood transfusion

Journal of Pediatric Hematology/Oncology

Volumn 35, Issue 4, 2013, Pages

  Ansari, Saqib H ^a   Shamsi, Tahir S ^a   Munzir, Saima ^a   Khan, Mohammed T ^a   Erum, Sajida ^a   Perveen, Kousar ^a   Farzana, Tasneem ^a   Ashraf, Mushtaq ^a   Mehboob, Tabassum ^a   Moinuddin, Moinuddin ^a  

^a National Institute of Blood Disease and Bone Marrow Transplantation   (Pakistan)

Author keywords

thalassemia; HbF augmentation; Hydroxyurea; Pakistan; Xmn I polymorphism

Indexed keywords

HEMOGLOBIN; HYDROXYUREA; ENDODEOXYRIBONUCLEASE XMNI; TYPE II SITE SPECIFIC DEOXYRIBONUCLEASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DNA POLYMORPHISM; DRUG DOSE ESCALATION; DRUG SAFETY; FEMALE; GENE; GLOBIN GAMMA XMN I GENE; HEMATOLOGICAL PARAMETERS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS;

BETA-THALASSEMIA; CHILD, PRESCHOOL; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; FEMALE; HUMANS; HYDROXYUREA; MALE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES;

MLCS; MLOWN;

EID: 84878636089     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31827e8662     Document Type: Article

References (13)

1. Aγ ratio, age at first blood transfusion and clinical features in b-thalassemia patients from Western Iran. Mol Biol Rep. 2010;37:159-164.
2. Gilman JG, Huisman THJ. DNA sequence variation associated with elevated fetal Gg globin production. Blood. 1985;66:783-787.
3. 0- thalassemia chromosome. Blood Cells Mol Dis. 2011;46:133-138.
4. Sharma N, Das R, Kaur J, et al. Evaluation of the genetic basis of phenotypic heterogeneity in north Indian patients with thalassemia major. Eur J Hematol. 2010;84:531-537.
5. Koren A, Levin C, Dgany O, et al. Response to hydroxyurea therapy in β-thalassemia. Am J Hematol. 2008;83:366-370.
6. Bradai M, Abad MT, Pissard S, et al. Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia. Blood. 2003;102:1529-1530.
7. Agouti I, Badens C, Abouyoub A, et al. Genotypic correlation between six common β-thalassaemia mutations and the XmnI polymorphism in the Moroccan population. Hemoglobin. 2007;31:141-149.
8. Winichagoon P, Fucharoen S, Chen P, et al. Genetic factors affecting clinical severity in β-thalassaemia syndromes. J Pediatr Hematol Oncol. 2000;22:573-580.
9. Alebouyeh M, Moussavi F, Haddad-Deylami H, et al. Hydroxyurea in the treatment of major b-thalassaemia and importance of genetic screening. Ann Hematol. 2004;83:430-433.
10. Taher A, Sheikh-Taha M. Hydroxyurea use in Lebanese patients with b-thalassaemia intermedia. J Pediatr Hematol Oncol. 2005;27:380-385.
11. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. Pediatr Hematol Oncol. 2005;27:380-385.
12. Panigrahi I, Dixit A, Arora S, et al. Do a-deletions influence hydroxyurea response in thalassaemia intermedia? Hematology. 2005;10:61-63.
13. Dixit A, Chatterjee TC, Mishra P, et al. Hydroxyurea in thalassaemia intermedia - a promising therapy. Ann Hematol. 2005;84:441-446.